microcap canadian biotech with phase 3 drug for ovarian ca nearing completion; antibody to ca marker that stimulates immunity, Ph 2 showed 14 mo longer to relapse, (? dendreon like play) 8/13: research report made available thru yahoo message board by Diggs Deep (he was paid to write report); very in depth and positive (with caveats)

ultra speculative microcap biotech with drug delivery nanotechnology. (boom or bust)

microcap china pharma; earnings growth 8/11:recent blog on seeking alpha

microbeads for diagnostic ultrasound (cardio); poss use as drug delivery vehicle in future 8/11: recent blog on Zachs.com positive comments

biotech with new approach= antibody to inner cell membrane lipid thats normally not exposed , but is in virally infected cells and virus membranes and cancer cells. studies in HepB, HepC, Cancer.; 7/07 pvt place @ .75

china biopharma growing internally and by acquisitions; restructured RACP(RimAsiaCapitalPartners)loan for acquisition of EyrePharma into redeemable preferred; was accumulating ave cost.294, but moved up so now watching

antibody base therapies (BITE) technology to stimulate killer T-cells to targeted AG's; pvt pl raised 25mill(9.2millsh +.5 wt exercis@3.09) 2.69/unit=investors included Baker Brothers, Omega fund, NGN Biomed Opportunity; Ph 1 MT103 for non-hodgeking Lymphoma; Ph2 on MT201 w docetaxel in mets breast CA(recvd 10mill milestone payment from Serono); graphically seems to be baselining.

Autoimmune= rx based on oral immune tolerance. Colloral originally pursued as a drug therapy now being marketed as a nutritional for arthritis patients; Two studies of tolerance rx for MS: Oral (copaxone)licensed to teva. , and Injectible protein MBP8298 licensed to BioMS in ph2 studies; Protein AI401 in ph3 studies in Type 1 DM;